VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Daratumumab and isatuximab in the treatment of multiple myeloma

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the use of anti-CD38 monoclonal antibodies in the treatment of multiple myeloma. There are currently two approved drugs of this kind: daratumumab and isatuximab. Daratumumab is approved as a first-line drug in the transplant-eligible population, and it is also approved in the relapsed/refractory (R/R) population. In contrast, isatuximab is currently only approved in the R/R setting; however, clinical trials evaluating isatuximab in combination with various agents in the frontline setting have reported positive results. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter